Cumberland Pharmaceuticals (NASDAQ: CPIX) reported Q1 EPS of $0.01, $0.08 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $8.5 million.

At March 31, 2021, Cumberland had $93.3 million in total assets including $24.9 million in cash and cash equivalents. Total liabilities were $46.5 million, including $15.0 million outstanding on the Company's revolving line of credit, resulting in total shareholders\' equity of $47.0 million.

For earnings history and earnings-related data on Cumberland Pharmaceuticals (CPIX) click here.